歐洲抗體發現市場：依產品、技術和國家分類－分析與預測（2025-2035）

歐洲抗體發現市場預計將從 2025 年的 32.3 億美元成長到 2035 年的 101.3 億美元，2025 年至 2035 年的複合年成長率為 12.11%。

在強大的生物醫學研究生態系統、尖端工程技術以及自動化和人工智慧日益普及的推動下，歐洲抗體發現市場正快速發展。對全人源和人源化抗體的需求不斷成長是一項重要的發展趨勢，反映了歐洲對降低免疫抗原性、安全性和特異性的重視。噬菌體展示、基因改造動物模型和糖基化工程等平台為早期計劃的嚴謹轉化研究提供了支持，同時也促進了針對自體免疫疾病、感染疾病和腫瘤的標靶藥物的開發。

同時，歐洲企業正將自動化、人工智慧驅動的建模、次世代定序和高通量篩檢等技術結合，以加速抗體的選擇和最佳化。對產學研合作和受託研究機構的日益依賴，正在提升專業技術的擴充性和可用性。單域抗體、抗體藥物複合體和雙特異性抗體等創新技術的湧現，拓展了治療的可能性，即使面對基因和細胞療法的競爭，也為歐洲的長期成長奠定了基礎。

市場介紹

憑藉著雄厚的大學科學研究實力、現代化的醫療基礎設施以及不斷湧現的創新生物技術公司，歐洲的抗體研發產業正崛起為全球生物製劑生態系統的重要組成部分。歐洲匯集了許多世界一流的研究機構和製藥公司，為腫瘤學、免疫學、感染疾病和罕見疾病領域的抗體研發創造了有利環境。對標靶精準藥物日益成長的需求，使抗體成為優先治療方法，並推動了全部區域對早期藥物研發和平台創新的持續投資。

歐洲市場以技術創新為特徵。對提高安全性、特異性和臨床成功率的需求推動了全人源抗體和人源化抗體的應用。糖基化工程、基因改造動物模型和噬菌體展示是常用的藥物發現平台，而自動化、次世代定序和高通量篩檢則簡化了抗體的鑑定和最佳化。同時，機器學習和人工智慧正被整合到藥物發現流程中，以改善可開發性評估、親和性成熟和標靶選擇。

製藥公司、生物技術公司、受託研究機構)和大學之間的緊密合作也是歐洲抗體發現領域的顯著特徵。將越來越多的發現活動外包給專業的 CRO，有助於提高規模化生產和成本效益。儘管面臨高昂的研發成本和其他療法的競爭等挑戰，但發現方法的持續創新和有利的法規結構，使歐洲抗體發現市場具備了長期成長和戰略重要性的優勢。

市場區隔:

細分 1：依產品/服務

• 產品
• 服務

細分2：依技術

• 噬菌體展示技術
• 融合瘤技術
• 單B細胞技術
• 基因改造動物技術
• 其他

細分3：按地區

• 歐洲

歐洲抗體發現市場的趨勢、促進因素與挑戰

市場趨勢

• 人工智慧和機器學習在標靶辨識、抗體設計和先導藥物最適化的應用正在加速，縮短了發現的時間。
• 新一代抗體形式，如雙特異性抗體、抗體藥物複合體（ADC）、奈米抗體和工程化片段，正被擴大應用。
• 擴展我們的端到端藥物發現平台，該平台整合了濕實驗室篩檢和計算生物學。
• 人們越來越依賴受託研究機構(CRO) 和專業服務供應商進行抗體發現和早期開發。
• 更重視功能優先和轉化性檢測（包括基於細胞和疾病相關的篩檢模型）。

主要市場促進因素

• 癌症、自體免疫疾病和慢性疾病領域對標靶生物製藥的需求強勁且持續。
• 製藥公司加大研發投入，以及大量創業投資資金湧入專門從事抗體技術的Start-Ups新創公司。
• 單細胞分析、高通量篩檢、定序和微流體取得了技術進展。
• 成本和生產力壓力正在推動外包和基於平台的藥物發現模式的發展。
• 歐洲主要市場為生物製藥和精準醫療創造了有利的法規環境。

主要挑戰

• 高品質、標準化的資料集有限，無法充分訓練和檢驗人工智慧驅動的藥物發現模型。
• 先進的藥物研發平台和數位基礎設施需要高昂的資本和營運成本；
• 人工智慧設計的抗體和共用資料集的複雜智慧財產權所有權。
• 人工智慧驅動的藥物發現結果的檢驗、可重複性和核准過程方面存在監管不確定性。
• 服務供應商和技術平台分散，導致供應商選擇和基準測試變得困難。

產品/創新：本報告幫助您辨識歐洲抗體發現市場的高價值機會。報告重點在於藥物發現平台、工程技術和治療應用領域中由創新主導的成長。報告提供研發投資策略、技術應用和產品線最佳化的指南，幫助您優先推進先導化合物化合物的發現、候選藥物的檢驗和抗體的最佳化。

成長/行銷：本報告深入分析了區域市場採納趨勢、新興市場和夥伴關係機會，旨在為企業製定策略性市場進入和商業化規劃提供支援。企業可以藉此識別產品、技術、應用領域和終端用戶細分市場的成長潛力。了解區域研發投入、法規結構和技術採納率，有助於企業最佳化行銷、授權和合作策略，從而在競爭激烈的市場環境中最大限度地提高知名度並提升投資回報率。

競爭分析：本報告提供全面的公司概況、競爭基準分析，並重點介紹策略聯盟、資金籌措活動、併購以及技術應用趨勢。相關人員可以清楚了解競爭對手的關注領域、研發重點和市場定位。這些洞察有助於企業識別差距並預測市場變化，從而製定差異化策略、最佳化市場進入策略，並在抗體發現生態系統中保持領先地位。

目錄

執行摘要

第1章 市場：產業展望

• 監管狀態/合規性
  • 歐洲聯盟
• 定價分析
  • 依產品
  • 按地區
• 供應鏈分析
• 價值鏈分析
• 專利分析
  • 按國家/地區
  • 公司
• 市場動態
  • 趨勢、促進因素、挑戰與機會：現況與未來影響評估（2024-2035年）
  • 市場趨勢
  • 市場促進因素
  • 市場挑戰
  • 市場機遇

第2章 區域

• 區域概況
• 歐洲
  • 區域概覽
  • 市場成長促進因素
  • 成長抑制因素
  • 透過提供
  • 透過技術
  • 按國家/地區

3. 市場－競爭標竿分析與公司概況

• 產品映射
  • 公司
  • 透過提供
  • 透過技術
• 管道分析
• 公司簡介
  • Genmab A/S

第4章調查方法

This report can be delivered in 2 working days.

Introduction to Europe Antibody Discovery Market

The Europe antibody discovery market is projected to reach $10.13 billion by 2035 from $3.23 billion in 2025, growing at a CAGR of 12.11% during the forecast period 2025-2035. The market for antibody discovery in Europe is developing quickly thanks to robust biomedical research ecosystems, cutting-edge engineering technologies, and growing automation and artificial intelligence adoption. The increasing demand for totally human and humanized antibodies is a significant development that reflects Europe's emphasis on reduced immunogenicity, safety, and specificity. Phage display, transgenic animal models, and glycoengineering are examples of platforms that support translational rigor in early-stage projects while facilitating the development of targeted medicines for autoimmune, infectious, and oncology disorders.

Simultaneously, European businesses are combining automation, AI-driven modeling, next-generation sequencing, and high-throughput screening to speed up antibody selection and optimization. Scalability and availability to specialized skills are being improved by a greater dependence on academic-industry partnerships and contract research companies. By expanding therapeutic potential through innovations in single-domain antibodies, antibody-drug conjugates, and bispecific antibodies, Europe is positioned for long-term growth even in the face of competition from gene and cell therapies.

Market Introduction

The European antibody discovery industry is emerging as a vital component of the global biologics ecosystem, bolstered by a solid foundation of university research, modern healthcare infrastructure, and a growing number of innovative biotech firms. A favorable environment for antibody discovery in oncology, immunology, infectious illnesses, and uncommon disorders is created by the presence of some of the top research institutes and pharmaceutical companies in the world in Europe. Antibodies have become the preferred therapeutic modality due to the growing demand for targeted and precision therapeutics, which has led to a continuous investment in early-stage discovery and platform innovation throughout the region.

The European market is distinguished by technological innovation. The desire to increase safety, specificity, and clinical success rates is driving the adoption of both completely human and humanized antibodies. Glycoengineering, transgenic animal models, and phage display are common discovery platforms, and automation, next-generation sequencing, and high-throughput screening are simplifying antibody identification and optimization. Simultaneously, machine learning and artificial intelligence are being included into discovery workflows to improve developability evaluation, affinity maturation, and target selection.

Strong cooperation between pharmaceutical corporations, biotechnology businesses, contract research organizations, and university institutions is another feature of the antibody discovery scene in Europe. Scalability and cost-effectiveness are made possible by the growing outsourcing of discovery tasks to specialist CROs. The European antibody discovery market is positioned for long-term growth and strategic significance due to ongoing innovation in discovery methods and supporting regulatory frameworks, despite obstacles such high development costs and competition from other modalities.

Market Segmentation:

Segmentation 1: By Offering

• Product
• Services

Segmentation 2: By Technology

• Phage Display Technology
• Hybridoma Technology
• Single B-Cell Technologies
• Transgenic Animal-based Methods
• Other Technologies

Segmentation 3: By Region

• Europe

Europe Antibody discovery Market Trends, Drivers and Challenges

Market Trends

• Accelerated adoption of AI and machine learning for target identification, antibody design, and lead optimization, reducing discovery timelines.
• Growing use of next-generation antibody formats such as bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and engineered fragments.
• Expansion of integrated, end-to-end discovery platforms combining wet-lab screening with computational biology.
• Rising reliance on CROs and specialized service providers for antibody discovery and early development.
• Increased focus on function-first and translational assays, including cell-based and disease-relevant screening models.

Key Market Drivers

• Strong and sustained demand for targeted biologics in oncology, autoimmune disorders, and chronic diseases.
• Increasing R&D investments by pharmaceutical companies and venture funding for antibody-focused biotech startups.
• Technological advancements in single-cell analysis, high-throughput screening, sequencing, and microfluidics.
• Cost and productivity pressures encouraging outsourcing and platform-based discovery models.
• Supportive regulatory outlook for biologics and precision medicine across major European markets.

Major Challenges

• Limited availability of high-quality, standardized datasets to fully train and validate AI-driven discovery models.
• High capital and operational costs associated with advanced discovery platforms and digital infrastructure.
• Complexity in intellectual property ownership for AI-designed antibodies and shared datasets.
• Regulatory ambiguity around validation, reproducibility, and approval pathways for AI-enabled discovery outputs.
• Fragmentation across service providers and technology platforms, making vendor selection and benchmarking difficult.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Regulatory Landscape / Compliance
  • 1.1.1 E.U.
    • 1.1.1.1 Germany
    • 1.1.1.2 France
    • 1.1.1.3 Italy
• 1.2 Pricing Analysis
  • 1.2.1 By Product
  • 1.2.2 By Region
• 1.3 Supply Chain Analysis
• 1.4 Value Chain Analysis
• 1.5 Patent Analysis
  • 1.5.1 By Country
  • 1.5.2 By Company
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
  • 1.6.2 Market Trends
    • 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
    • 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
    • 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
  • 1.6.3 Market Drivers
    • 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
    • 1.6.3.2 Increasing Prevalence of Chronic Diseases
  • 1.6.4 Market Challenges
    • 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
    • 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
  • 2.2.5 By Technology
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Technology
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Technology
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Technology
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Technology
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Technology
    • 2.2.6.6 Sweden
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Technology
    • 2.2.6.7 Netherlands
      • 2.2.6.7.1 By Offering
      • 2.2.6.7.2 By Technology
    • 2.2.6.8 Rest-of-Europe
      • 2.2.6.8.1 By Offering
      • 2.2.6.8.2 By Technology

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Product Mapping
  • 3.1.1 By Company
  • 3.1.2 By Offering
  • 3.1.3 By Technology
• 3.2 Pipeline Analysis
• 3.3 Company Profiles
  • 3.3.1 Genmab A/S
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products/Product Portfolio
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Target Customers
    • 3.3.1.5 Key Personal
    • 3.3.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Antibody Discovery Market (by Scenario), $Billion, 2024, 2030, and 2035
• Figure 2: Antibody Discovery Market (by Region), $Billion, 2024 and 2035
• Figure 3: Europe Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
• Figure 4: Europe Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
• Figure 5: Antibody Discovery Market, Value Chain Analysis
• Figure 6: Antibody Discovery Market, Patent Analysis (by Country), January 2022- August 2025
• Figure 7: Antibody Discovery Market, Patent Analysis (by Company), January 2022- August 2025
• Figure 8: Europe Antibody Discovery Market, $Billion, 2024-2035
• Figure 9: U.K. Antibody Discovery Market, $Billion, 2024-2035
• Figure 10: Germany Antibody Discovery Market, $Billion, 2024-2035
• Figure 11: France Antibody Discovery Market, $Billion, 2024-2035
• Figure 12: Italy Antibody Discovery Market, $Billion, 2024-2035
• Figure 13: Spain Antibody Discovery Market, $Billion, 2024-2035
• Figure 14: Sweden Antibody Discovery Market, $Billion, 2024-2035
• Figure 15: nds Antibody Discovery Market, $Billion, 2024-2035
• Figure 16: Rest-of-Europe Antibody Discovery Market, $Billion, 2024-2035
• Figure 17: Antibody Discovery Market, Product Mapping (by Company)
• Figure 18: Data Triangulation
• Figure 19: Top-Down and Bottom-Up Approach
• Figure 20: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Pricing Analysis (by Region)
• Table 3: Antibody Discovery Market (by Region), $Billion, 2024-2035
• Table 4: Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 5: Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 6: U.K. Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 7: U.K. Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 8: Germany Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 9: Germany Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 10: France Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 11: France Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 12: Italy Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 13: Italy Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 14: Spain Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 15: Spain Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 16: Sweden Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 17: Sweden Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 18: Netherlands Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 19: Netherlands Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 20: Rest-of-Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 21: Rest-of-Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 22: Antibody Discovery Market, Product Mapping (by Offering)
• Table 23: Antibody Discovery Market
• Table 24: Pipeline Analysis